Inflammatory Bowel Disease

Understanding Ulcerative Colitis and the coMra Approach

Ulcerative colitis is a condition characterized by inflammation and the development of open sores, or ulcers, within the colon. This case report examines a 47-year-old male patient who was diagnosed with ulcerative colitis in 1990. Initially, his condition was localized as proctosigmoiditis. However, by 2014, a colonoscopy confirmed that the condition had progressed to pancolitis, with inflammation and ulceration affecting the entire colon.

Prior to beginning coMra therapy, the patient experienced severe symptoms, including abdominal pain and cramping during relapses, which he rated as an 8 to 10 on a 10-point pain scale. He suffered from 12 to 14 diarrheal stools per day during these relapses, averaging three to four relapses annually. These episodes were consistently accompanied by the presence of blood and mucus in the stool, as well as significant fatigue and weight loss.

The coMra Therapy Protocol

To address these challenges, the patient utilized the Delta 980, the home-user version of the coMra Delta device. The treatment plan was designed for daily application, specifically twice per day for an initial 20-day course. Following the significant results observed after this first course, the treatment regimen was modified and reduced in cooperation with his therapists.

Regarding concurrent pharmacotherapy, the patient had been using oral and suppository anti-inflammatories specifically designed for the colon. At the start of his coMra therapy, he was averaging five to six pills daily. Once he began treatment, he was able to discontinue the use of nightly suppositories, and he has since reduced his oral medication to two pills per day.

Clinical Results and Quality of Life

To monitor progress, the patient utilized fecal calprotectin testing – a non-invasive marker for ulcerative colitis. In September 2013, his marker was 312, a positive indicator of the disease. Following the start of care, his levels fluctuated, but from February 2016 to the present, testing has indicated no active ulcerative colitis.

The patient’s quality of life has improved significantly: * Bowel Function: He has moved from an average of five diarrheal bowel movements per day to one well-formed stool per day. * Pain Management: He has experienced no relapses, pain, or cramps since beginning coMra therapy, a marked improvement from his previous 8–10/10 pain levels. * Dietary Freedom: He currently has no dietary restrictions, with the sole exception of avoiding milk.

Conclusion

This case highlights the potential of coMra therapy to support the body’s healing capacity and improve quality of life. We extend our gratitude to our Slovakian representative, Jana Vudinova, for her contributions to this case, and to all those who participated in our 2016 annual conference in Greece.

As Théun Mares, the founder of Radiant Life Technologies, once noted: "The state of well-being is something that has to be experienced before one even knows that it exists. Once it has been discovered, it needs to be nurtured and tended with care." coMra therapy remains a beautiful way to nurture that sense of well-being.